Eli Lilly announces direct-to-patient portal for new weight loss drug; The latest health stories from around the world
Eli Lilly, maker of the anti-obesity drug Zepbound, announced last week the launch of LillyDirect, a direct-to-patient portal, allowing some patients to obtain its drug for as little as $25 a month. The move is seen as a major shift in the way these popular medications can reach patients. https://www.medscape.com/s/viewarticle/eli-lilly-offers-obesity-drug-directly-consumers-2024a10000fl? For many of the 42 million Americans with obesity, weight …
